Three Key Updates in HIV Treatment: EACS Guidelines
The latest EACS HIV treatment recommendations bring three important changes: a broader eligibility for dolutegravir/lamivudine, a revised approach to the historical M184V resistance mutation, and expanded consideration of long-acting injectable therapy for selected patients who have not achieved viral suppression.
12 November 2026 07:49
New HIV Antibody Treatment Shows Promise — But Who Would Benefit Most?
Could long-acting antibody treatment make HIV care easier for older adults? New findings presented at HIV Drug Therapy Glasgow 2026 suggest potential benefits for people managing multiple medications. But with only 20 participants and 24 weeks of follow-up, ...
More
11 November 2026 10:00
How Switzerland Prevented Hundreds of HIV Diagnoses With PrEP — and Who Is Still Being Left Behind
Switzerland’s national PrEP strategy may have helped avert an estimated 268 HIV diagnoses, according to findings presented at HIV Drug Therapy Glasgow 2026. But the benefits remain unevenly distributed: women account for just 1–2% of PrEP users, highlighting ...
More
About Life4me+
One of the main goals of Life4me+ — is to prevent new cases of HIV and other STIs, hepatitis C and tuberculosis. So we talk about HIV and other diseases: how to protect yourself from them, how to live with them.
More
Campaign U=U (#UequalsU)
The information and education campaign "U=U" ("Undetectable equals untransmittable", #UequalsU, #НравноН), organized by Life4me + in the Eastern Europe and Central Asia region, aimed at disseminating information that an HIV-positive person with an undetectable viral load can not transmit the virus to another person sexually.
Many studies have shown that in a sero-discordant couple where the HIV-positive partner took ARV therapy and maintained an undetectable viral load, there were no reported cases of sexual transmission of HIV.
Our Partners
